Scarica l'app Stockscreener
2.00
1.96%
-0.04
Dopo l'orario di chiusura:
1.96
-0.04
-2.00%
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché PHIO Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$2.04
Aprire:
$2.03
Volume 24 ore:
135.31K
Relative Volume:
0.05
Capitalizzazione di mercato:
$9.60M
Reddito:
-
Utile/perdita netta:
$-11.66M
Rapporto P/E:
-0.2452
EPS:
-8.156
Flusso di cassa netto:
$-11.09M
1 W Prestazione:
+14.29%
1M Prestazione:
+1.01%
6M Prestazione:
-26.47%
1 anno Prestazione:
-70.45%
Intervallo 1D:
$1.95
$2.03
Intervallo di 1 settimana:
$1.71
$2.08
Portata 52W:
$0.9657
$9.79
Phio Pharmaceuticals Corp Stock (PHIO) Company Profile
Nome
Phio Pharmaceuticals Corp
Settore
Industria
Telefono
(508) 767-3861
Indirizzo
11 APEX DRIVE, SUITE 300A, MARLBOROUGH, MA
Confronta PHIO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PHIO
Phio Pharmaceuticals Corp
|
2.00 | 8.40M | 0 | -11.66M | -11.09M | -8.156 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Phio Pharmaceuticals Corp Stock (PHIO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2020-08-05 | Iniziato | H.C. Wainwright | Buy |
Phio Pharmaceuticals Corp Borsa (PHIO) Ultime notizie
Best Value Stocks to Buy for May 28th - Zacks Investment Research
New Strong Buy Stocks for May 28th - The Globe and Mail
New Strong Buy Stocks For May 28th - Barchart.com
Phio Pharmaceuticals (NASDAQ:PHIO) Trading 2.8% Higher – Time to Buy? - Defense World
Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference - Newsfile
Phio Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update - Newsfile
Phio Cancer Treatment Shows Breakthrough Results: 44% Complete Response Rate in Latest Clinical Trial Data - Stock Titan
Metric Deep Dive: Understanding Phio Pharmaceuticals Corp (PHIO) Through its Ratios - DWinneX
Phio Pharmaceuticals Reports Positive Phase 1b Trial Results - TipRanks
Phio reports positive results in skin cancer trial - Investing.com
Phio reports positive results in skin cancer trial By Investing.com - Investing.com India
Phio Pharmaceuticals Announces Positive Pathology Results in Third Cohort in INTASYL PH-762 Skin Cancer Clinical Trial - Newsfile
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series - Newsfile
Phio Pharmaceuticals (PHIO) to Release Earnings on Thursday - Defense World
Best Value Stocks to Buy for April 23rd - NewsBreak: Local News & Alerts
Analysts Advise You To Maintain Your Position In Phio Pharmaceuticals Corp (NASDAQ: PHIO) - Stocksregister
Best Momentum Stocks to Buy for April 23rd - TradingView
Ratio Revelations: Shuttle Pharmaceuticals Holdings Inc (SHPH)’s Financial Metrics in the Spotlight - DWinneX
Financial Snapshot: Analyzing Phio Pharmaceuticals Corp (PHIO)’s Key Ratio Metrics - DWinneX
Understanding the Risks of Investing in Phio Pharmaceuticals Corp (PHIO) - knoxdaily.com
Phio Pharmaceuticals Corp (PHIO) deserves closer scrutiny - uspostnews.com
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
As Cancer Rates Climb, Wall Street Turns Its Gaze Toward New Frontiers in Cancer Treatments - Baystreet.ca
Contrasting Phio Pharmaceuticals (NASDAQ:PHIO) and RespireRx Pharmaceuticals (OTCMKTS:RSPI) - Defense World
Equities Analysts Offer Predictions for PHIO FY2025 Earnings - Defense World
PHIO Stock Soars as Safety Panel Clears Skin Cancer Drug for Next Dose - MSN
3 Penny Stocks to Watch Now, 4/10/25 - TipRanks
Phio Pharmaceuticals Stock Soars On Clearance To Escalate Dose In Skin Cancer Treatment Trial: Retail’s Thrilled - MSN
Phio advances skin cancer treatment with successful trial By Investing.com - Investing.com South Africa
This Biotech Is Ripping Following Phase 1b Trial Announcement - The Globe and Mail
Crude Oil Down 4%; Neogen Shares Plunge After Q3 ResultsBloom Energy (NYSE:BE), Neogen (NASDAQ:NEOG) - Benzinga
Phio Pharmaceuticals Advances PH-762 Cancer Treatment in Phase 1 - GuruFocus
PHIO Advances PH-762 in Phase 1b Clinical Trial for Skin Cancers - GuruFocus
Is Phio’s Surge Sustainable? - timothysykes.com
Phio Pharmaceuticals Potential Skin Cancer Treatment Recommended for Dose Escalation - marketscreener.com
Phio advances skin cancer treatment with successful trial - Investing.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Study to Fourth Dose Escalation Cohort - Newsfile
Breakthrough in Skin Cancer Trial: PH-762 Shows 100% Tumor Clearance as Study Advances - Stock Titan
Phio stock hits 52-week low at $0.99 amid sharp annual decline - Investing.com
Phio Pharmaceuticals’ (PHIO) Buy Rating Reaffirmed at HC Wainwright - Defense World
Phio stock hits 52-week low at $0.99 amid sharp annual decline By Investing.com - Investing.com South Africa
H.C. Wainwright maintains Buy on Phio Pharma, target at $4.00 - Investing.com Australia
H.C. Wainwright maintains Buy on Phio Pharma, target at $4.00 By Investing.com - Investing.com India
Phio Pharmaceuticals Corp Azioni (PHIO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.89%
3.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):